Table 2.
angiogenic drugs adverse events among FIII studies.
| Drug | HTA | Thrombo-embolic events A/V |
Intestinal Perforation |
Proteinu-ria | Fatigue | Neutropenia | Anaemia | Thrombocytopenia | Diarrhoea | Oedema | Palmoplantar erythrodysesthesia |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bevacizu-mab4-13 | Any grade: 26% G3/4: 6–17.8% |
Any grade: 11% G3/4: 0.7–6.7% |
G3/4: 0–2.2% | Any grade: 14% G3/4: 0.7–9.7% |
NR | Any grade: 29% G3/4: 17–63.3% |
NR | Any grade: 12% G3-4: 3–12% |
NR | NR | NR |
| Pazopanib17,18 | Any grade: 5.77% G3/4: 30.8% |
NR | NR | Any grade: 8.4% G3/4:1.3% |
Any grade 41.5% G3/4:2.7% |
Any grade: 31.7% G3/4: 9.9% |
NR | Any grade: 15.8% G3/4:2.5% |
Any grade: 53% G3/4: 8.2% |
NR | Any grade:13.4% G3/4: 1.9% |
| Nintedanib14.15 | Any grade 15% G3/4: 5% |
Any grade: 8% G3/4: 5% |
Any grade 4% G3/4: 2% |
NR | Any grade: 59% G3/4: 7% |
Any grade: 33% G3/4: 20% |
Any grade: 43% G3/4: 13% |
Any grade: 38% G3/4: 18% |
Any grade: 77% G3/3: 22% |
NR | NR |
| Cediranib20,22 | Any grade: 35–45% G3/4: 5–12% |
Any grade: 5% G3/4: 3% |
G3/4: <1% | Any grade: 18% G3/4: 1% |
Any grade: 77–79% G3/4: 6–16% |
Any grade: 29–69% G3/4: 6–26% |
NR | Any grade: 27–47% G3/4: 2–8% |
Any grade: 86–92% G3/4 : 1–11% |
NR | NR |
| Trebananib16,19 | Any grade: 11% G3/4 1% |
<2% | <2% | <2% | Any grade: 24–57% G3/4: 3% |
Any grade: 16% G3/4: 5% |
Any grade: 9–10% G3/4: 1% |
NR | Any grade: 27% G3/4: 2% |
Any grade: 61–71% G3/4: 19–21% |
Any grade: 69% G3/4: 22% |
NR = not reported.